Clinical Trial: Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Efficacy of Tranexamic Acid Taken Orally in Patients With Hereditary Hemorrhagic Telangiectasia
Brief Summary:
Hereditary hemorrhagic telangiectasia (HHT, Rendu-Osler-Weber Syndrome) is associated with frequent nosebleeds in the majority of cases. Several reports in the literature support the use of antifibrinolytics like Tranexamic acid to reduce nosebleeds. The objectives of the study are to test if Tranexamic acid taken orally can
- improve anemia (lead to an increased hemoglobin level)
- reduce nosebleeds.
Detailed Summary:
Sponsor: University Hospital, Saarland
Current Primary Outcome: Change of hemoglobin level within the phases. [ Time Frame: Beginning and end of each 3 months period. ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Mean epistaxis score (daily duration multiplied by mean subjective daily intensity) [ Time Frame: Measured once a day during each 3 months period ]
Original Secondary Outcome: Same as current
Information By: University Hospital, Saarland
Dates:
Date Received: December 11, 2009
Date Started: March 2002
Date Completion:
Last Updated: December 12, 2009
Last Verified: December 2009
